Posts Tagged ‘Diabetic Retinopathy’
How Regeneron Aims to Stay on Message With VR/AR APP
Virtual reality has been used to train surgeons, to evaluate balance control and associated fall risk in glaucoma patients, and, more recently, to create simulations that allow users to better understand the visual effects of various eye diseases. To the latter, Regeneron and Intouch Solutions have developed and released the In My Eyes smartphone app.…
Read MoreAlimera Sciences: Addressing DME with Persistent Microdose Therapy
Alimera Sciences is focused on the commercialization of ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema (DME), which received FDA approval in 2014. The product is currently marketed in the US and three European countries, and is approved in 14 others. Alimera is gaining traction in the market, with over 6,000 eyes treated to…
Read MoreRegeneron: Pursuing Combination Therapies with PDGFR-beta and Ang2
Regeneron Pharmaceuticals Inc. markets the highly successful anti-VEGF injection EYLEA (aflibercept), which is FDA approved for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME) and diabetic retinopathy (DR) in patients with DME. Global EYLEA sales in 2015 totaled $4.1 billion, including OUS sales by Bayer.…
Read MoreGoogle–Moorfields Venture Eyes AI to Speed Diagnosis with OCT
Google’s DeepMind Health artificial intelligence project and Moorfields Eye Hospital in London have teamed up for a five-year venture to develop an algorithm using one million anonymized retina scans from the Moorfields’ database to speed up and improve diagnosis of age-related macular degeneration (AMD) and diabetic retinopathy. Google and Moorfields announced the collaboration this month.…
Read MoreExploring the Keys to Combination Therapies in Retina
The keys to developing combination therapies to treat retinal diseases lie in clinicians being able to better identify biomarkers for disease progression, developing strategies for staging disease, and finding a place for agents that act on disease pathways other than vascular endothelial growth factor, say ophthalmology leaders. Participants at a breakfast panel at OIS@AAO explored…
Read MoreGoogle Lens Clinical Trials to Start in 2016
Novartis, through its Alcon eye-care division, intends to start clinical trials of an accommodative Google “smart” contact lens in human eyes next year, Novartis Chief Executive Joe Jimenez told the Swiss French-language newspaper Le Temps last week. “This project is progressing well,” Jimenez told Le Temps reporter Willy Boder. “When we announced the agreement a…
Read MoreIs pSivida on the verge of megastar status?
With three of the four sustained-release drug delivery products commercially available in the U.S. and Europe, pSivida just might prove Wall Street pundits correct and score some big wins in the ophthalmic space. The Watertown, Mass.-based company’s Durasert technology can deliver drugs to the posterior segment for a predetermined amount of time ranging from months…
Read More